KPV Tripeptide (Lys-Pro-Val)
PeptideThe substantial discrepancy arises because the community judges considerably more positively based on subjective experiential reports [c1, c2, c3] than the medical evidence – exclusively preclinical animal and cell studies without human studies [s3, s4, s9] – justifies. Placebo effects and selection bias in self-reporting communities may explain the discrepancy.
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
KPV is an anti-inflammatory tripeptide with a plausible mechanism via melanocortin receptors and intestinal PepT1 uptake — but not a single human RCT has been published. All evidence comes from cell cultures and mouse colitis models; whether any of this translates to humans is genuinely unknown. Community reports are relatively consistent on IBD and skin improvements, which is biologically plausible but impossible to verify. Anyone using KPV is running an uncontrolled self-experiment with an open outcome.
Description
KPV is a synthetic tripeptide (Lys-Pro-Val) derived from the C-terminus of α-MSH with anti-inflammatory properties in preclinical models – no human data available [s1, s2].
KPV (Lysyl-Prolyl-Valine) is a naturally occurring tripeptide derived from the C-terminal segment (positions 11–13) of alpha-melanocyte-stimulating hormone (α-MSH) [s1]. It was originally identified because it retains much of the anti-inflammatory activity of the parent peptide without producing its pigmentation-enhancing effects [s3]. Existing research is limited exclusively to in vitro cell models and animal studies (primarily mouse models of colitis and skin inflammation). No clinical human studies (RCTs or cohort studies) have been published to date [s3, s4]. In preclinical studies, KPV demonstrated efficacy in intestinal explants and DSS/TNBS-induced colitis models in mice, with nanomolar concentrations sufficient to inhibit NF-κB and MAP kinase signaling pathways [s4, s5]. Uptake into intestinal cells occurs via the peptide transporter PepT1 (SLC15A1), whose expression is upregulated in inflamed tissue, suggesting a theoretical selectivity advantage for inflamed intestinal tissue [s4, s5]. For skin applications, preclinical evidence exists for reduction of IL-1β production and oxidative stress in keratinocytes [s6]. Nanoparticle-based formulations (e.g., hyaluronic acid-functionalized nanoparticles) have been developed preclinically to improve oral bioavailability [s7]. A combined formulation with FK506 in nanoparticles showed synergistic effects in colitis mouse models [s8]. Given the complete absence of human studies, KPV should be regarded exclusively as a research chemical. Any therapeutic application in humans is experimental and scientifically unsubstantiated [s3, s9].
Legal Status (DE)
KPV is not approved as a medicinal product in Germany and is used exclusively for research purposes. In the United States, the FDA has officially nominated KPV (as free base and acetate salt) for inclusion in the Section 503A Bulk Drug Substances List. On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) will evaluate KPV in a public meeting (Docket No. FDA-2025-N-6895). [s18] Previously, KPV was classified under FDA Category 2; this classification was lifted in April 2026 after the nomination was withdrawn — however, this does not constitute approval for compounding. [s18] A final decision on inclusion in the 503A list has not yet been made.
Mechanism of Action
KPV acts on inflammatory processes via two complementary mechanisms: 1. Melanocortin receptor-mediated inhibition: KPV binds to melanocortin receptors, particularly MC1R and MC3R, on immune cells and epithelial cells. Via MC3R activation, nuclear import of the NF-κB subunit p65/RelA is inhibited, reducing transcription of pro-inflammatory genes (TNF-α, IL-1β, IL-6) [s1, s2]. 2. PepT1-mediated intracellular uptake: In the gastrointestinal tract, KPV is actively transported via the oligopeptide transporter PepT1 (SLC15A1) into epithelial cells and immune cells. This mechanism is independent of melanocortin receptor binding and likely dominates with oral administration in the gut. Nanomolar KPV concentrations intracellularly inhibit activation of NF-κB and MAP kinase signaling pathways and reduce secretion of TNF-α, IL-1β, and IL-6 [s4, s5]. PepT1 is upregulated in inflamed colonic tissue (e.g., in colitis), which theoretically favors selective accumulation of KPV in inflamed areas [s4, s5]. Important note: Both mechanisms have been demonstrated exclusively in vitro and in animal models. Transferability to humans has not been scientifically established [s3, s9].
Dosing
Darmentzündung (oral, präklinisch abgeleitet)
- Dose
- 500 mcg
- Frequency
- 1× täglich morgens
- Route
- oral
- Duration
- 4–8 Wochen (kein belegter Standard)
- Timing
- Fasted, in the morning
- With food
- vermeiden
Systemische Entzündung (subkutan, inoffizielles Protokoll)
- Dose
- 500 mcg
- Frequency
- 1× täglich
- Route
- injektion-subkutan
- Duration
- kein belegter Standard
- Timing
- no evidence-based recommendation
- With food
- optional
Sublingual (inoffizielles Protokoll)
- Dose
- 200–500 mcg
- Frequency
- 1× täglich
- Route
- sublingual
- Duration
- kein belegter Standard
- Timing
- Hold under the tongue for 60 seconds
- With food
- optional
No officially substantiated upper limit exists. All dosing information is based on unofficial community protocols without clinical validation. No regulatory-recommended maximum daily dose [s10, s11].
All dosing recommendations are hypothetical and extrapolated from the biohacking community or animal study data – without basis in human studies. Human use is exclusively experimental. KPV is not an approved medicinal product [s12, s13].
Calculate reconstitution, plan dosing, look up injection technique
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Lokale Reaktionen an der Injektionsstelle (Rötung, Schmerz, Schwellung) Typical for subcutaneous peptide injections; not systematically investigated in preclinical studies, occasionally mentioned in community reports [s9, c2]. | gelegentlich | leicht |
| Gastrointestinale Beschwerden (Blähungen, veränderte Stuhlkonsistenz) Occasionally reported by community users with oral administration; no systematic documentation in human studies [s9, c3]. | gelegentlich | leicht |
| Allergische Reaktion / Überempfindlichkeit Theoretical risk for all exogenous peptides; no case reports specifically documented for KPV in available literature [s9]. | selten | moderat |
| Unbekannte systemische Langzeiteffekte Long-term human safety data are entirely lacking. Chronic modulation of NF-κB and melanocortin receptors could theoretically cause immunosuppression or impairment of physiological inflammatory responses [s1, s2, s3]. | theoretisch | schwer |
Contraindications
Inhibition of NF-κB and immune modulation could theoretically interfere with tumor control mechanisms. No human safety data available [s2, s3].
No safety data whatsoever available for pregnancy or lactation; precautionary principle applies [s3, s9].
Additive immunosuppression through combination with other anti-inflammatory substances is possible; no human interaction data available [s3].
Unpredictable interactions with ongoing immunomodulatory therapies possible; no clinical data available [s2, s3].
Interactions
Synergistic
KPV inhibits pro-inflammatory signaling pathways (NF-κB, NLRP3) via MSH receptors, while GHK-Cu promotes tissue repair and antioxidant gene expression (via Nrf2); both peptides are mechanistically complementary in wound healing and inflammation modulation.
KPV and liposomal curcumin act synergistically on the NF-κB signaling cascade: KPV inhibits intracellular translocation of NF-κB via melanocortin receptors, while curcumin inhibits IκB kinase, thereby reducing inflammatory cytokine production at multiple levels simultaneously.
Thymosin Alpha-1 modulates the adaptive immune response through maturation and differentiation of T-lymphocytes, whereas KPV primarily attenuates innate immunity and inflammatory responses; the theoretical synergy arises from complementary immunoregulatory effects on distinct arms of the immune system.
Studies
Tier C — Low Evidence
Community Evidence
Top reported benefits
- Subjective improvement of IBD symptoms (ulcerative colitis, Crohn's disease)
- Reduction of gastrointestinal complaints and improved stool
- Improvement of skin condition with concurrent intestinal and topical application
- Better nutrient absorption following intestinal calming
- Reduced joint and inflammatory pain
Top reported issues
- High costs and uncertain product quality
- Unclear onset of action; no perceptible effect in some cases
- Procurement difficulties and legal uncertainty
Many users combine KPV with other peptides (particularly BPC-157), which complicates attribution of individual effects [c1, c4]. The legal grey area and lack of product standards are recognized as problems by users themselves. No community user reported serious adverse events, though reporting bias is likely [c2, c3].
Scientific Sources
- Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists
Getting SJ, Riffo-Vasquez Y, Pitchford S, et al. (2008). American Journal of Respiratory Cell and Molecular BiologyCPMID:18441283DOI - KPV Peptide Dosage: All Routes
PeptidesExplorer editorial team (2024). PeptidesExplorer.comDLink - KPV Dosing: 500mcg AM, 5-On/2-Off Protocol (2026)
ThePeptideCatalog editorial team (2025). ThePeptideCatalog.comDLink - What's Changing With Peptide Regulation in 2026
BSCG editorial team (2025). BSCG.orgBLink - KPV: The Anti-Inflammatory Peptide Under FDA Review
HealingMaps editorial team (2025). HealingMaps.comCLink - Immobilized alpha-melanocyte stimulating hormone 10-13 (GKPV) inhibits tumor necrosis factor-alpha stimulated NF-kappaB activity
Bhardwaj R, Bhardwaj K, Bhardwaj P, et al. (2006). PeptidesCPMID:16310876DOI - A PepT1 mediated medicinal nano-system for targeted delivery of cyclosporine A to alleviate acute severe ulcerative colitis
Luo Q et al. (2019). International Journal of PharmaceuticsCPMID:31408067 - Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review
Medsci review authors (2025). Journal of Medical Sciences (medsci.org)CLink - GHK-Cu + KPV + BPC-157 Blend: Skin Repair and Anti-Inflammatory Research
PeptideProtocolWiki (secondary/educational source) (2026). CLink - July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee — 503A Bulk Drug Substances
U.S. Food and Drug Administration (2026). CLink - α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs
Luger TA, Scholzen T, Grabbe S (1997). Clinical Experimental ImmunologyBPMID:9193386DOI - KPV Peptide: Benefits, Uses, and What the Research Shows
Superpower.com editorial team (2024). Superpower.comCLink - PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. (2008). GastroenterologyCPMID:18061177DOI - Melanocortin-derived tripeptide KPV has anti-inflammatory effects in intestinal mucosal cells
Dalmasso G, Nguyen HTT, Charrier L, et al. (2008). Regulatory PeptidesCPMID:18092346DOI - KPV Peptide Protects Against Fine Dust-Induced Skin Inflammation
Unknown authors (preclinical study cited in review) (2025). Tissue & CellCLink - Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
Xiao B, Laroui H, Viennois E, et al. (2017). Molecular TherapyCPMID:28143741DOI - PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced Colitis
Zhang Y, Wang X, Liu J, et al. (2024). Frontiers in PharmacologyCDOI - KPV Peptide | Benefits, Safety & Buying Advice
Innerbody Research editorial team (2025). Innerbody.comCLink
Community Sources
Storage
Unopened
Store lyophilized at -20 °C; protect from light and moisture.
Opened
Store reconstituted solution at 4 °C for a maximum of 4 weeks; do not refreeze.
Notes
KPV is relatively stable as a tripeptide; nevertheless, precise storage and handling conditions must be maintained for research purposes. No validated stability data for human formulations are available.